The CRISPR-Cas9 system has revolutionized gene editing with its high efficiency and specificity, offering new avenues for targeted cancer therapy. This review focuses on the mechanisms through which CRISPR-Cas9 can be used to suppress oncogenes, restore tumor suppressor genes, and enhance immunotherapy by editing key genetic sequences. This review also explores how CRISPR-Cas9 targets DNA repair pathways such as homology-directed repair (HDR) and non-homologous end joining (NHEJ), emphasizing the precision required for successful cancer treatment. Despite promising in vitro results and ongoing clinical trials, challenges such as off-target effects and immune responses remain. This review also highlights advances in CRISPR technology, preclinical and clinical studies, combination therapies, and future directions in cancer therapy.
No takes yet. Share an insight, caveat, or question.
Paul-Chima et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: